Compare Quest Diagnostics Inc (DGX) vs Nvidia Corp (NVDA) Price & Performance

Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.

DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.

NVIDIA (NVDA) trades at $208.23, up 2.31% on the day, with a bullish technical signal from moving averages. The stock shows exceptional fundamental strength with revenue soaring to $130.5B in 2025 and net income margins reaching 62.97%. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.87 surpassing the $1.76 estimate. The company maintains robust profitability metrics including 74.15% gross margins and 114.29% ROE, though valuation ratios remain elevated with P/E at 32.43 and P/S at 20.44.

The outlook remains positive with strong analyst consensus (75.32% buy ratings) and a $325.86 price target suggesting significant upside. Key opportunities include continued AI chip dominance and expanding market opportunities, while risks include increased competition, potential peak AI infrastructure spending, and elevated valuation multiples that could limit near-term growth. The stock's proximity to its 52-week high warrants monitoring of momentum sustainability.